Research video featuring Dr. Sai Chavala
A selected video link provided for the research and media section.
Open on YouTubeArticles, research coverage, and media featuring Dr. Sai Chavala and Retina of North Texas.
The 2026 Nobel Prize recognized the discovery of light-gated ion channels and optogenetics, the foundational work of Karl Deisseroth, Peter Hegemann and Georg Nagel. Nanoscope Therapeutics used optogenetics to develop MCO-010, an investigational gene therapy for retinitis pigmentosa now under FDA review. Dr. Chavala served as Nanoscope’s first Chief Medical Officer and was an investigator in its clinical development.
A profile of Dr. Chavala's research in cellular reprogramming and future-oriented vision restoration. We present it humbly as part of the broader scientific effort to develop better options for patients with blinding retinal disease.
Selected video coverage and research media related to Dr. Chavala’s retina research and vision-restoration work.
A selected video link provided for the research and media section.
Open on YouTubeLinks are collected from the current Retina of North Texas news page and additional requested media coverage.
North Texas innovation coverage highlighting research projects shaping the future.
Read MoreRecognition from the ARVO Foundation for clinician-scientist impact.
Read MoreFeature story on research focused on restoring vision in macular degeneration.
Read MoreScience coverage of direct cellular reprogramming work.
Read MoreAAO EyeNet coverage of photoreceptor-like cell development.
Read MoreOriginal Nature publication on pharmacologic reprogramming into photoreceptor-like cells.
Read MoreNEJM commentary indexed on PubMed.
Read MorePatient-facing safety commentary on recalled artificial tear drops.
Read MoreAdditional retina specialist media coverage requested for the news page.
Read MoreAssociated Press coverage featuring Dr. Chavala's perspective on Tony Romo's eye condition.
Read MoreAn exclusive Q&A on sustained vision-restoration results at 3 years, with Dr. Chavala speaking as a clinical trial investigator alongside Stanford's Dr. Vinit Mahajan.
Read MoreThe FDA has accepted Nanoscope Therapeutics' Biologics License Application for MOGENRY (MCO-010). Dr. Chavala served as Nanoscope's first Chief Medical Officer and was an investigator in the clinical development of MCO-010.
Read MoreThe STARLIGHT Phase 2 trial in Stargardt disease (EClinicalMedicine, 2025) and “A synthetic opsin restores vision in patients with severe retinal degeneration” (Molecular Therapy, 2025). Both describe investigational therapy studied in clinical research.
STARLIGHT Trial PaperSynthetic Opsin PaperDisclosure: Dr. Chavala served as Nanoscope Therapeutics' first Chief Medical Officer and has served as a consultant and advisor to the company. MCO-010 is investigational and has not been approved by the FDA.